



Jupiter Life Line Hospitals Limited

November 07, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: - Investor Presentation for the quarter and half year ended September 30, 2025

Reference: Unaudited Financial Results for the quarter and half year ended September 30, 2025
(Standalone and Consolidated) of the Company.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2025.


This will also be available on the Company's Website at www.jupiterhospital.com.

You are requested to kindly take the afore-mentioned on record and oblige.

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

IN THE PINK OF HEALTH.



Jupiter Life Line Hospitals Limited

Results Presentation – Q2 & H1FY26

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



Dr. Ankit Thakker
JMD & CEO

Patient First

“It has been an uneventful quarter, with all our existing hospitals performing as per expectations. As outlined earlier, Pune is nearing maturity, and the Indore hospital is showing improved growth following the brownfield expansion that was undertaken earlier this year.


The Dombivli Hospital project is progressing on schedule. From this quarter, we have moved towards the interiors, services and finishing stages of the hospital and will begin with team building soon.

As committed last quarter, we have begun with the construction work for our South Pune facility from Q3FY26. We hope to commence operations of this facility in CY28.

We continue to leverage our operational strengths, clinical excellence and patient-centric approach to drive sustainable growth and reinforce our leadership position in Western India’s healthcare sector.”

Q2FY26 Performance Highlights


Rs in Cr



*This is the Operational Income and EBITDA. Unbilled revenue and Doctors' provision are excluded

H1FY26 Performance Highlights


Rs in Cr




*This is the Operational Income and EBITDA. Unbilled revenue and Doctors' provision are excluded

H1FY26 Operating Metrics


Operational Bed Capacity⁽¹⁾




Average Occupancy Rate⁽²⁾




IPD & OPD Volumes ('000)⁽³⁾




ARPOB⁽⁴⁾



ALOS (in Days)⁽⁵⁾



Payor Mix



ARPOB rounded off to the nearest hundred *This is the Operational Income and EBITDA. Unbilled revenue and Doctors' provision are excluded

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.

Consolidated Profit & Loss Statement

Profit and Loss (in Rs. Crs)	Q2FY26	Q2FY25	YoY	Q1FY26	QoQ	H1FY26	H1FY25	YoY	FY25
Revenue from Operations	376.8*	320.0	11.7%	337.9	5.8%	714.7*	604.5	15.1%	1,245.4
Other Income - Operational	16.8	15.0		15.1		31.9	28.4		57.0
Total Income	393.6	335.1	17.5%	353.0	11.5%	746.6	632.9	18.0%	1,302.4
Cost of Goods Sold	73.8	66.0		70.7		144.5	122.2		255.5
Gross Profit	319.9	269.1	18.9%	282.2	13.3%	602.1	510.7	17.9%	1,046.9
Gross Profit Margin	81.3%	80.3%		80.0%		80.6%	80.7%		80.4%
Employee Cost	63.2	56.2		61.7		125.0	109.6		225.2
Professional Fees	103.0 [#]	78.3		82.7		185.7 [#]	148.4		305.3
Other Expenses	61.4	56.5		59.4		120.8	108.7		216.3
EBITDA	92.2	78.1	18.1%	78.4	17.6%	170.7	144.1	18.5%	300.1
EBITDA Margin	23.4%	23.3%		22.2%		22.9%	22.8%		23.0%
Depreciation	21.5	14.4		21.2		42.7	25.4		57.1
EBIT	70.8	63.7	11.1%	57.2	23.7%	128.0	118.6	7.9%	243.0
EBIT Margin	18.0%	19.0%		16.2%		17.1%	18.7%		18.7%
Other Income - Finance	11.3	7.4		12.8		24.1	14.3		28.3
Finance Cost	7.8	1.2		8.3		16.1	2.3		10.7
PBT	74.2	70.0	6.1%	61.7	20.2%	136.0	130.6	4.1%	260.7
PBT Margin	18.9%	20.9%		17.5%		18.2%	20.6%		20.0%
Tax	16.8	18.2		17.8		34.6	34.4		66.9
PAT	57.4	51.7	11.0%	43.9	30.7%	101.4	96.3	5.3%	193.8
PAT Margin	14.6%	15.4%		12.5%		13.6%	15.2%		14.9%
Basic EPS	8.75	7.88		6.69		15.44	14.63		29.47

*Operational revenue includes unbilled revenue of Rs 19.2 cr

#Professional Fees include additional provision of Rs 12.3 cr towards unsettled outstanding receivables

Consolidated Balance Sheet

Equity & Liabilities (in Rs. Crs)	Sep-25	Mar-25
Total Equity	1,450.9	1,356.3
Share Capital	65.6	65.6
Other Equity	1,385.4	1,290.6
Non-Controlling interest	0.0	0.1
Non-Current Liabilities	398.2	395.8
Financial Liabilities		
Borrowings	318.9	321.7
Lease liabilities	70.4	62.3
Provisions	5.9	4.7
Deferred Tax Liabilities	3.0	7.1
Current Liabilities	173.7	158.4
Financial Liabilities		
Borrowings	4.5	4.0
Lease liabilities	9.7	5.1
Trade Payables	52.4	69.1
Other financial Liabilities	69.9	51.3
Other Current Liabilities	23.9	23.4
Current tax liabilities (net)	11.4	3.5
Provisions	1.9	2.0
Total Equity & Liabilities	2,022.8	1,910.5

Assets (in Rs. Crs)	Sep-25	Mar-25
Non - Current Assets	1,332.7	1,217.9
Property Plant & Equipments	892.8	899.4
Right of use assets	100.5	74.0
CWIP	296.4	185.1
Other Intangible assets	4.2	4.6
Financial Assets		
Investments	0.1	0.1
Other Financial Assets	32.2	53.5
Other Non - Current Assets (Net)	6.5	1.2
Current Assets	690.1	692.5
Inventories	27.6	26.5
Financial Assets		
Investments	526.2	509.8
Trade receivables	75.7	43.2
Cash and cash equivalents	26.2	92.5
Bank balances other than above	3.4	2.5
Other financial assets	7.9	-
Current tax assets (net)	9.3	6.2
Other Current Assets	13.8	11.9
Total Assets	2,022.8	1,910.5

Consolidated Cash Flow Statement

Profit and Loss (in Rs. Crs)	H1FY26	H1FY25
Net Profit Before Tax	136.0	130.6
Adjustments for: Non -Cash Items / Other Investment or Financial Items	41.6	23.2
Operating profit before working capital changes	177.6	153.8
Changes in working capital	-13.7	2.5
Cash generated from Operations	163.9	156.3
Direct taxes paid (net of refund)	-33.8	-32.9
Net Cash from Operating Activities	130.1	123.4
Net Cash from Investing Activities	-173.2	-122.8
Net Cash from Financing Activities	-23.2	-8.3
Net Decrease in Cash and Cash equivalents	-66.3	-7.7
Add: Cash & Cash equivalents at the beginning of the period	92.5	26.4
Cash & Cash equivalents at the end of the period	26.2	18.7

Scaling up for better care: Setting up New hospitals

Location	Expected Bed Addition Phase I	Expected Bed Addition Phase II	Total Bed Capacity	Capex Estimated (Rs in cr)	Expected to Operationalise	Current Status of Phase I
Dombivli	200-220	280-300	500	500	Q1FY27	Project is on track
Pune South (Bibwewadi)	200-220	280-300	500	500	CY28	Construction has begun in Q3FY26
Mira - Bhayandar	150-170	130-150	300	400	CY29	On the drawing board

Total Existing Beds

1,061



Addition of Beds

~1,440*



Total Beds Capacity

~2,500



Jupiter Life Line Hospitals Limited

CIN: L85100MH2002PLC137908

investor.relations@jupiterhospital.com



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mandar Chavan / Rahul Agarwal
mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net
+91 96993 82195 / +91 98214 38864

Thank You